Health is not the absence of disease. It is the presence of vitality.
That distinction — simple to state, radical in its implications — is the idea at the heart of longevity medicine. And it is the idea that the longevity clinic sector is, in many cases, getting wrong.
We are in the middle of a gold rush. In 2020, longevity clinics were a niche experiment. In 2026, they are a global industry. Over 800 clinics operate in the United States alone. Investment in longevity reached $8.5 billion in 2024 across 325 deals, with average deal sizes tripling. Fountain Life raised $108 million. Franchise models like Serotonin Centers have crossed 100 locations. SHA Wellness and Clinique La Prairie are expanding into Asia and the Middle East. Neko Health is making advanced diagnostics accessible at scale.
But the signal that matters most is not coming from startups. It is coming from institutions. Weill Cornell has launched a 12-month Longevity Medicine Programme. Northwestern has opened a Human Longevity Clinic. Mayo Clinic is building its own programme. Sheba Medical Center became the first academic institution with a dedicated longevity centre. Abu Dhabi has created the first government regulatory framework for longevity medicine on the planet.
When medical schools add curriculum and governments write regulations, a field has arrived. The question is no longer whether longevity medicine is real. The question is who will define what "good" looks like — and whether you, as a consumer of these services, can tell the difference.
A Sector Growing Faster Than Its Foundations
A landmark survey of 82 longevity clinics across the US, Europe, Asia, Australia, and Brazil — conducted by Longevity.Technology in 2025 — provides the most comprehensive snapshot of the industry to date. The findings reveal an industry with enormous potential and significant structural problems.
Over a third of surveyed clinics offer stem-cell treatments. Twenty-eight percent offer Botox. Thirty-five percent offer hair loss treatments. Thirty-eight percent provide facial rejuvenation procedures. As Andrea Maier, co-founder of the Healthy Longevity Medicine Society, observed: the distinction between longevity medicine and aesthetic medicine remains deeply blurred. The majority of clinics are prescribing pharmaceutical drugs off-label for ageing — medications approved for specific medical conditions, being used for a purpose for which no drug has yet received approval. Some of these, particularly in younger and otherwise healthy adults, have shown potentially detrimental effects when used without rigorous clinical oversight.
A separate survey of 288 clinics attempted to classify them by scientific legitimacy. Only around 10% focused primarily on evidence-based interventions. Roughly 25% offered experimental but scientifically plausible treatments while acknowledging their investigational nature. The remaining 65% fell into categories ranging from dubious to pseudoscientific.
And here is the paradox that should concern both practitioners and consumers: despite annual fees that can reach six figures, only 39% of surveyed clinics reported being profitable. Yet 77% had plans to expand. High ambition, low profitability, inconsistent science — this is a sector that has scaled faster than its foundations can support.
The clinics that are losing money are, in many cases, the ones built on the wrong model: heavy capital expenditure on real estate and equipment, broad menus of expensive treatments, and high patient acquisition costs through digital marketing — without the clinical depth or outcome tracking to justify the investment. On the other end, digital platforms offer algorithmic protocols with no physician oversight and no accountability for what happens when the protocol fails. Neither model is what the market actually needs.
The Central Error: Interventions Without Understanding
At the heart of the problem lies a structural flaw in how most clinics operate. They work backwards.
The typical model begins with a menu of treatments — peptide injections, IV nutrient infusions, NAD+ drips, hormone replacement protocols, exosome therapies, hyperbaric oxygen — and then finds clients to sell them to. The client walks through the door and, regardless of their unique biology, receives some variation of the same protocol. Perhaps with a blood test or two layered on top to create the appearance of personalisation.
This is retail healthcare. It is not precision medicine.
A peer-reviewed editorial published in Aging in October 2025 by Marco Demaria stated it plainly: exotic supplements and intravenous cocktails are too often sold with minimal validation and experimental biologics offered without robust safety data. Commercial incentives, in too many cases, overcome scientific rationale. The interpretation of diagnostics is equally problematic — tools like epigenetic clocks and telomere-length tests are presented to clients as definitive biological age "scores" when their precision and clinical utility remain under active debate. Multi-omics profiles, when offered at all, are frequently delivered without proper integrative analysis and clear actionable meaning.
The consequences of this "intervention first, biology second" approach extend beyond wasted money. Without understanding a person's unique biological terrain — their genome, their metabolic state, their microbiome, their inflammatory profile — any intervention is a shot in the dark. What helps one person may be useless for another. And what is harmless for one may be actively counterproductive for someone with a different biological configuration.
The Nuance on Interventions: Promise, Caution, and Intellectual Honesty
This is where the conversation requires nuance that much of the current debate lacks.
The strict clinical trial purist will say: if there is no randomised controlled trial showing lifespan extension in humans, it is not evidence-based. But here is the reality: for most longevity interventions, such trials do not exist and may not exist for decades. Demonstrating that something extends human lifespan requires following people for 30 to 50 years. No pharmaceutical company will fund that study for an unpatentable compound. No government agency is prioritising it. The clinical trial infrastructure was built for acute disease and drug approval, not for the slow, multi-factorial, decades-long process of ageing.
Does that mean we should dismiss everything that lacks a completed RCT? No. That would be intellectually dishonest and practically paralysing.
What it means is that we need a more sophisticated framework for evaluating interventions — one that distinguishes between levels of evidence and levels of risk, and that acknowledges the difference between "no evidence of effect" and "evidence of no effect."
Take peptides as an example. BPC-157, one of the most discussed compounds in longevity circles, has strong preclinical data — 35 out of 36 published studies are animal studies, with only a single small human case series. It is not FDA-approved and consumer products are unregulated. That is the reality. But it is equally true that many practitioners report meaningful clinical observations in tissue repair and recovery. The honest position is not that BPC-157 is proven — it is not. Nor is it that BPC-157 is worthless — the preclinical signal is real. The honest position is that it is a promising compound that should be used, if at all, under clinical supervision, with informed consent, with appropriate safety monitoring, and with a clear-eyed acknowledgement that we are working ahead of the published evidence.
The same logic applies to stem-cell therapies, exosomes, NAD+ infusions, and other regenerative interventions. Some of these show genuine promise not just in extending lifespan — the bar that is nearly impossible to clear with current trial designs — but in improving current function. Regenerating tissue. Reducing inflammation. Restoring organ performance. Accelerating recovery. Making people feel and perform better now, not just live longer later.
A good longevity clinic does not pretend these interventions are proven when they are not. But neither does it refuse to offer anything that lacks a 20-year RCT. It occupies the intellectually honest middle ground: stratifying interventions by evidence level, being transparent with clients about what is established and what is investigational, monitoring outcomes rigorously, and adjusting protocols based on individual biological response.
The clinics that will fail — both scientifically and commercially — are the ones that offer unproven interventions without this framework. The ones that will succeed are those that combine clinical curiosity with scientific discipline.
What "Biology First" Actually Means
If the central failure of most longevity clinics is starting with interventions and working backwards, the solution is conceptually straightforward: start with biology and work forwards.
A rigorous longevity practice begins with deep biological assessment — understanding the unique terrain of each individual's health at a molecular level before recommending a single intervention.
Genomics provides the basic blueprint of what your cells can produce, but it is not deterministic. It reveals inherited predispositions — not destinies, but probabilities that can be largely modulated through lifestyle and targeted nutritional choices.
Epigenomics captures how those genes are actually being expressed during your lifetime. Epigenetic ageing clocks — particularly validated models like GrimAge and DunedinPACE — can estimate biological age and pace of ageing with increasing precision. But they must be understood as tracking tools, not verdicts. It is the trajectory over time — measured every six to twelve months — that reveals whether interventions are working.
Metabolomics provides a real-time snapshot of cellular energy production, nutrient processing, and metabolic health. It can detect mitochondrial stress, early insulin resistance, and metabolic dysfunction long before conventional tests flag a problem.
Advanced blood and functional panels go far beyond the standard medical screening that checks whether you are "sick." A standard blood panel misses critical dimensions of suboptimal function — hormonal imbalances, micronutrient deficiencies, deeper inflammatory markers, metabolic health indicators, organ function subtleties, heavy metal burden. Organic acids testing, comprehensive hormone panels (like DUTCH), and expanded biomarker panels with 100+ markers reveal the difference between "not sick" and "truly optimised."
Microbiome analysis maps the hidden ecosystem that influences immune regulation, the gut-brain axis, inflammatory signalling, metabolic function, and far more. Ignoring this layer is like trying to understand a rainforest by looking only at the tree canopy while ignoring the entire undergrowth — the plants, animals, insects, fungi, and bacteria that make the ecosystem function.
The critical point: any one of these data layers alone is incomplete. A genome tells you about potential but not current state. A blood test tells you about today but not trajectory. An epigenetic clock tells you about biological age but not what is driving the ageing. The value emerges from integrating them — building a systems biology model of an individual's health. And that integration demands genuine scientific expertise, supported by AI-powered bioinformatics, from practitioners who understand not just individual biomarkers but the complex interactions between biological systems.
Without systems-level interpretation, data is noise. With it, data becomes a roadmap for precisely targeted intervention.
Red Flags: How to Spot a Clinic That Is Selling, Not Treating
A treatment menu that exists before your data does. If a clinic's website prominently features its list of therapies before mentioning diagnostic assessment, the business model is built around selling interventions, not understanding your biology.
Aesthetic services marketed as longevity. Botox and facial rejuvenation may have psychological value — feeling more youthful when looking in the mirror can genuinely affect wellbeing. But they are not longevity interventions. A clinic that conflates looking younger with ageing slower is engaging in deliberate category confusion.
Cookie-cutter protocols. If every client receives substantially the same programme regardless of their individual data, the clinic is not practising personalised medicine. It is running a production line.
No baseline biological assessment before intervention. You would not accept a heart medication without a cardiac evaluation. Why accept a longevity protocol without a thorough understanding of your biology?
Biological age tests presented as definitive answers. These are valuable tracking tools, not standalone diagnostics. A clinic that hands you a number without explaining limitations, longitudinal tracking needs, and the specific drivers behind the result is oversimplifying the science.
No outcome tracking or follow-up. If a clinic does not plan to remeasure your biomarkers at regular intervals to assess whether interventions are working, there is no accountability loop. Without measurement, there is no feedback. Without feedback, there is no science — only faith.
Green Flags: What a Science-Driven Longevity Practice Gets Right
Comprehensive biological assessment comes first. The clinical journey begins with deep phenotyping across multiple dimensions. No intervention is recommended until data has been collected, integrated, and interpreted.
Interventions are evidence-stratified and transparently communicated. Proven lifestyle interventions form the foundation. Established pharmacological interventions are used where clinically indicated. Promising but investigational therapies are offered with full transparency about their evidence status, informed consent, and rigorous safety monitoring. The client always knows where on the evidence spectrum each recommendation sits.
Every protocol is genuinely personalised. Two clients with the same chronological age may need radically different strategies. Their longevity programmes should reflect their different genomic risks, metabolomic signatures, microbiome compositions, inflammatory burdens, and epigenetic trajectories in every detail.
Outcomes are tracked longitudinally. Biomarker reassessment at regular intervals — every three, six, or twelve months depending on the marker — creates the accountability loop that separates science from speculation. If an intervention is not moving biology in the right direction, it is adjusted or discontinued.
Multidisciplinary expertise. Longevity sits at the intersection of molecular biology, genomics, nutrition science, exercise physiology, clinical medicine, data science, and AI. A serious practice brings together expertise across these domains — not a single practitioner trying to do everything.
Transparency about uncertainty. The most credible clinics do not claim to reverse ageing. They do not guarantee outcomes. They acknowledge the limits of current science while explaining how they navigate those limits. This honesty is not a weakness — it is the hallmark of genuine scientific practice. And paradoxically, it is what builds the deepest client trust and the most sustainable business.
Beyond Lifestyle: What Moves the Needle From "Not Sick" to "At Your Best"
The strongest evidence for extending healthspan belongs to interventions that rarely make headlines because they are neither novel nor expensive. Consistent physical exercise — combining resistance training and cardiovascular conditioning — remains the single most validated longevity intervention available. Nutritional optimisation, sleep quality, and stress management are foundational. These are not glamorous, but their evidence base is robust, reproducible, and grounded in decades of human data.
But the goal of longevity medicine is not merely avoiding disease. It is optimising function — moving people from "not sick" to performing at their best. This is where the field gets genuinely interesting, and where a good clinic differentiates itself from a conventional practice.
Targeted supplementation — when guided by individual biological data — can meaningfully move the needle. Mitochondrial support compounds like CoQ10 and PQQ address cellular energy production at its source. Anti-inflammatory interventions targeting specific pathways identified through biomarker analysis can modulate the chronic low-grade inflammation that drives age-related decline. Senolytic compounds like fisetin and quercetin are showing early promise in clearing senescent cells. Nootropics and neurocognitive support — when personalised to an individual's neurochemistry and genetic predispositions — can enhance cognitive performance and resilience. Hormone optimisation, when guided by comprehensive testing and monitored rigorously, can restore vitality that naturally declines with age.
Beyond supplements, interventions like hyperbaric oxygen therapy, photobiomodulation, cold and heat exposure protocols, and structured fasting regimens have varying levels of evidence but genuine mechanistic rationale. Some individuals respond dramatically to interventions that others barely notice — which is precisely why biological assessment must precede intervention.
The frontier therapies — peptides, stem cells, exosomes, NAD+ infusions — occupy a different category. They are promising. Some practitioners observe meaningful clinical benefits. But the published human evidence remains thin. A responsible clinic positions these as what they are: investigational interventions offered under medical supervision, with informed consent, tracked outcomes, and the intellectual honesty to acknowledge that we are working at the edge of current knowledge. This is not a reason to refuse them entirely. It is a reason to use them wisely.
The Business Model That Actually Works
There is a white space in this market that few are discussing openly.
On one side sit capital-intensive brick-and-mortar clinics spending millions on real estate, equipment, and overhead before seeing their first patient. On the other, digital platforms with no physicians, no clinical judgment, and no accountability. In between, concierge medicine practices with loyal patient bases but zero longevity expertise and no roadmap to build it.
None of these is what the market actually needs.
The sustainable longevity practice — the one that is both scientifically rigorous and commercially viable — looks different. It serves a carefully curated client base, typically 200 to 400 individuals who value depth over breadth. It operates with a small, focused, multidisciplinary team. It competes not on price or marketing spend but on outcomes — measurable, trackable, defensible results that clients can see in their own data.
This model works financially because it builds something that no franchise or platform can replicate: a genuine clinical relationship, grounded in deep biological understanding, tracked with longitudinal outcome data, and deepened over years. Clients stay because they see results. They refer because the results are real. The practice does not need to spend aggressively on patient acquisition because its retention and referral rates make paid marketing a supplement, not a lifeline.
The membership model — annual comprehensive assessment, quarterly or biannual retesting, ongoing protocol management, and regular consultations — creates predictable recurring revenue while aligning the clinic's financial incentives with the client's health outcomes. When you get paid to keep people optimised over years rather than to sell them a treatment menu, the economics and the science point in the same direction.
This is the practice that the institutions, regulators, and discerning consumers are looking for. The position is still wide open.
The Future We Should Be Building
The tools to do longevity medicine properly already exist. Multi-omics science has advanced dramatically. Biological ageing clocks are becoming more precise with every iteration. AI and machine learning can interpret multi-dimensional biological data at a scale and speed that was unthinkable a decade ago. Wearable devices provide continuous physiological monitoring that enriches the clinical picture in real time.
The question a good longevity clinic answers is not "what can we sell you?" It is "what does your biology actually need — and what is the most efficient path from where you are to where you want to be?"
That means starting with data, not treatments. It means being honest about evidence hierarchies while remaining open to promising science. It means tracking everything, adjusting constantly, and never confusing a protocol with a relationship. It means building a practice where the science and the business model reinforce each other — where doing the right thing for the client is also the right thing for the bottom line.
The longevity gold rush is real. The institutions are building. The governments are regulating. The franchises are scaling. The question is not whether this field will define the future of medicine — it will. The question is whether it will be built on solid science and genuine health optimisation, or on marketing promises that cannot survive scrutiny.
For anyone navigating this landscape — as a consumer, a practitioner, or an investor — that distinction is the only one that truly matters.
Arkana.Health provides strategic advisory for longevity clinics, wellness centres, and other businesses entering the longevity economy. Our experts also work with select individuals seeking science-grounded health optimisation on an exclusive and limited basis. For more on our approach, visit arkana.health.